Founded in 2012 by Alban Bessede, PhD in Immunology, with the support of Schiever retail group, Immusmol specializes in developing antibodies directed against small molecules. Supported by public institutions such as Bpifrance and the Regional Council of Nouvelle-Aquitaine, Immusmol is established in Bordeaux, France.
The Immusmol team is made up of around twenty talents with different backgrounds and application fields, bringing their expertise and experience to the company. We aim to become a natural choice for small molecule antibody development, hence working with distributors from all over the globe and collaborating with a worldwide network of scientists.
Our focus: validated tools for detecting small molecules
Immusmol stands for antibodies against small molecules. While traditional antibodies only recognize large molecules such as proteins, Immusmol designs and develops antibodies capable of targeting low molecular weight entities, below 900 Daltons, that can be used for conventional staining applications as well as in the scope of novel immunoassays development
Fully compatible with existing antibody-based technologies, small molecule antibodies are opening new possibilities in research diagnostic and therapeutic applications.
